Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/1/2026

1. SPY
2. AVAV
3. NVDA
4. EOSE
5. NKE
6. MU
7. DLR
8. AAPL
9. TSLA
10. VSH

Go back to Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

Sarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse

December 13, 2019 7:44 AM EST

Credit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $185.00) while maintaining an Outperform rating after the FDA approved Vyondys 53.

The company plans to price the drug at parity with Exondys 51 or >$600,000 for a... More

Sarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'

December 13, 2019 6:19 AM EST

RBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining an Outperform rating following approval of Vyondys 53/golodirsen.

The analyst commented, "We view tonight's approval of Vyondys 53/golodirsen as a significant win for SRPT,... More